Electrocardiogram Artificial Intelligence-Guided Screening for Low Ejection Fraction (EAGLE)

Mayo Clinic1 site in 1 country358 target enrollmentJune 26, 2019

ConditionsAsymptomatic Left Ventricular Systolic Dysfunction (Disorder)Heart Failure

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Asymptomatic Left Ventricular Systolic Dysfunction (Disorder)
Sponsor: Mayo Clinic
Enrollment: 358
Locations: 1
Primary Endpoint: New Diagnosis of Low Ejection Fraction (defined as ejection fraction ≤50%)
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.

Registry

clinicaltrials.gov

Start Date

June 26, 2019

End Date

November 1, 2020

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Mayo Clinic

Responsible Party

Principal Investigator

Xiaoxi Yao

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

•Primary care clinicians who are part of a participating care team that care for adult patients and have the ability to order ECG and TTE (this includes physicians, nurse practitioners, and physician assistants).